Blog
iRhythm Technologies Q2 Earnings Call Highlights
Key Points
- Interested in iRhythm Technologies? Here are five stocks we like better.
- Strong Q2 performance: Revenue rose 20.1% year over year to $224.2 million, while adjusted EBITDA reached
indie Semiconductor Q2 Earnings Call Highlights
Key Points
- Interested in indie Semiconductor, Inc.? Here are five stocks we like better.
- Second-quarter revenue rose 24% year over year to $64 million, exceeding the midpoint of guidance by $2
INmune Bio Q2 Earnings Call Highlights
Key Points
- Interested in INmune Bio, Inc.? Here are five stocks we like better.
- Regulatory and manufacturing progress: INmune Bio plans to seek conditional U.K. approval for Ebstrocel in late
Inogen Q2 Earnings Call Highlights
Key Points
- Interested in Inogen, Inc? Here are five stocks we like better.
- Second-quarter revenue rose 3% to $95.1 million, with international sales up 15% and new products helping offset a 2%
ICU Medical Q2 Earnings Call Highlights
Key Points
- Interested in ICU Medical, Inc.? Here are five stocks we like better.
- Strong second-quarter performance: Revenue reached $548 million, with organic growth of 6%; adjusted EBITDA
Hyperfine Q2 Earnings Call Highlights
Key Points
- Interested in Hyperfine, Inc.? Here are five stocks we like better.
- Revenue and system sales accelerated: Second-quarter revenue rose 45% year over year to $3.9 million, with 12
ICF International Q2 Earnings Call Highlights
Key Points
- Interested in ICF International, Inc.? Here are five stocks we like better.
- Q2 revenue was essentially flat at $474.5 million, as 6.6% growth in non-federal markets offset a 9.5%
Health Catalyst Q2 Earnings Call Highlights
Key Points
- Interested in Health Catalyst, Inc.? Here are five stocks we like better.
- Q2 revenue reached $70.5 million, above guidance, while adjusted EBITDA of $9.9 million landed at the high
Halozyme Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Halozyme Therapeutics, Inc.? Here are five stocks we like better.
- Record Q2 performance: Revenue rose 48% year over year to $481 million, while royalty revenue increased
Gevo Q2 Earnings Call Highlights
Key Points
- Interested in Gevo, Inc.? Here are five stocks we like better.
- Gevo raised its 2026 adjusted EBITDA outlook to more than $60 million, up from $30 million, supported by Canadian
Gen Digital Q1 Earnings Call Highlights
Key Points
- Interested in Gen Digital Inc.? Here are five stocks we like better.
- Gen Digital exceeded first-quarter guidance, with bookings and revenue each rising 11% year over year to $1.28
JFrog Q2 Earnings Call Highlights
Key Points
- Interested in JFrog Ltd.? Here are five stocks we like better.
- Strong Q2 performance: Revenue rose 29% year over year to $163.8 million, led by 53% cloud growth, increased security
Fox Factory Q2 Earnings Call Highlights
Key Points
- Interested in Fox Factory Holding Corp.? Here are five stocks we like better.
- Strong second-quarter execution: Revenue was $358.1 million, down 4.5% year over year, while adjusted
Five9 Q2 Earnings Call Highlights
Key Points
- Interested in Five9, Inc.? Here are five stocks we like better.
- Five9 exceeded Q2 expectations with revenue of $312 million, up 10% year over year, driven by 14% subscription growth
Full House Resorts Q2 Earnings Call Highlights
Key Points
- Interested in Full House Resorts, Inc.? Here are five stocks we like better.
- Strong quarterly performance: Full House Resorts reported a 5.6% increase in second-quarter revenue and a
Funko Q2 Earnings Call Highlights
Key Points
- Interested in Funko, Inc.? Here are five stocks we like better.
- Funko’s second-quarter sales rose 7% year over year, with particularly strong growth in Europe and core collectibles
Expensify Q2 Earnings Call Highlights
Key Points
- Interested in Expensify, Inc.? Here are five stocks we like better.
- Profitability and cash flow improved: Expensify reported $33.9 million in Q2 revenue, $6.4 million in free cash
electroCore Q2 Earnings Call Highlights
Key Points
- Interested in electroCore, Inc.? Here are five stocks we like better.
- Revenue rose 28% year over year to $9.5 million, driven by Veterans Affairs prescription sales and
Definium Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Definium Therapeutics, Inc.? Here are five stocks we like better.
- Key clinical catalysts are imminent: Definium expects VOYAGE Phase III generalized anxiety disorder
Dropbox Q2 Earnings Call Highlights
Key Points
- Interested in Dropbox, Inc.? Here are five stocks we like better.
- Dropbox returned to modest growth: Q2 revenue rose 0.9% year over year to $631.5 million, while paying users
Denali Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Denali Therapeutics Inc.? Here are five stocks we like better.
- AVLAYAH generated $3.6 million in its first full commercial quarter for Hunter syndrome, with payer
CryoPort Q2 Earnings Call Highlights
Key Points
- Interested in CryoPort, Inc.? Here are five stocks we like better.
- CryoPort reported Q2 2026 revenue of $49 million and achieved $400,000 in positive adjusted EBITDA from continuing
CVRx Q2 Earnings Call Highlights
Key Points
- Interested in CVRx, Inc.? Here are five stocks we like better.
- CVRx lowered its 2026 outlook due to sales-force turnover, slower territory-manager productivity ramps and
Cytokinetics Q2 Earnings Call Highlights
Key Points
- Interested in Cytokinetics, Incorporated? Here are five stocks we like better.
- MYQORZO’s U.S. launch is gaining traction: The drug reached 1,500 dispensed patients and more than 700
CytomX Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in CytomX Therapeutics, Inc.? Here are five stocks we like better.
- Varseta-M remains CytomX’s primary focus: The Phase I monotherapy study has enrolled 113 patients, with